tradingkey.logo

Catheter Precision Inc

VTAK
查看詳細走勢圖
1.770USD
-0.040-2.21%
收盤 12/24, 13:00美東報價延遲15分鐘
2.92M總市值
0.05本益比TTM

Catheter Precision Inc

1.770
-0.040-2.21%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.21%

5天

-19.55%

1月

-4.12%

6月

-62.51%

今年開始到現在

-79.34%

1年

-75.35%

查看詳細走勢圖

TradingKey Catheter Precision Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Catheter Precision Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名154/206位。機構持股佔比非常高,近一個月多位分析師給出公司評級為。最高目標價38.00。中期看,股價處於下降通道。近一個月,市場表現較差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Catheter Precision Inc評分

相關信息

行業排名
154 / 206
全市場排名
466 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
38.000
目標均價
+1753.66%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Catheter Precision Inc亮點

亮點風險
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
業績高增長
公司營業收入穩步增長,連續3年增長2900.00%
業績增長期
公司處於發展階段,最新年度總收入420.00K美元
估值高估
公司最新PE估值0.05,處於3年歷史高位
機構減倉
最新機構持股24.65K股,環比減少29.05%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.33

Catheter Precision Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Catheter Precision Inc簡介

Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
公司代碼VTAK
公司Catheter Precision Inc
CEOJenkins (David A)
網址https://www.ramed.com/

常見問題

Catheter Precision Inc(VTAK)的當前股價是多少?

Catheter Precision Inc(VTAK)的當前股價是 1.770。

Catheter Precision Inc 的股票代碼是什麼?

Catheter Precision Inc的股票代碼是VTAK。

Catheter Precision Inc股票的52週最高點是多少?

Catheter Precision Inc股票的52週最高點是15.681。

Catheter Precision Inc股票的52週最低點是多少?

Catheter Precision Inc股票的52週最低點是1.492。

Catheter Precision Inc的市值是多少?

Catheter Precision Inc的市值是2.92M。

Catheter Precision Inc的淨利潤是多少?

Catheter Precision Inc的淨利潤為-21.80M。

現在Catheter Precision Inc(VTAK)的股票是買入、持有還是賣出?

根據分析師評級,Catheter Precision Inc(VTAK)的總體評級為--,目標價格為38.000。

Catheter Precision Inc(VTAK)股票的每股收益(EPS TTM)是多少

Catheter Precision Inc(VTAK)股票的每股收益(EPS TTM)是36.353。
KeyAI